Almost every sermorelin protocol you will find says the same thing: take it at night. Almost none of them explain why beyond “that is when it works best,” which is true and also not an explanation. Here is the actual mechanism, and, just as importantly, the specific claim about timing that nobody has tested.
Growth hormone release is not a steady drip
Your pituitary does not release growth hormone at a constant background rate throughout the day. It releases GH in discrete pulses, separated by periods of very low secretion, and the pattern is not spread evenly across 24 hours. A physiology review puts it directly: “the release of GH is pulsatile with diurnal variation,” and among the specific factors known to affect that secretion are “sleep and exercise” [2]. The same review adds a detail rarely mentioned in commercial marketing: GH secretion differs by sex, with “male ‘pulsatile’ secretion versus female ‘continuous’ secretion” [2]. That is a real physiological distinction, separate from sermorelin’s own trial results, and it deserves to be known even though nothing here connects the two.
The practical upshot: your body already has a preferred time to release growth hormone, concentrated around sleep. A drug designed to prompt that release makes more physiological sense timed to work with that window than against it.
What the actual sermorelin trial did
The best-documented adult sermorelin trial did not dose participants randomly through the day. It dosed them nightly, by design, and the results describe exactly what that timing produced. Nightly subcutaneous sermorelin produced “an acute GH pulse within 10 minutes” of injection, lasting roughly two hours, and, measured across a full 12-hour overnight window, “12-h integrated nocturnal GH rose significantly vs. placebo in both sexes” [1]. That is a real, measured finding — nighttime dosing, in this trial, produced a fast, substantial, nocturnal GH increase. See how that nightly dose translates by body weight for the numbers behind the regimen itself.
What that finding does not establish is a comparison. Nobody ran the same trial with morning dosing and measured whether the effect was smaller, identical, or larger. The trial tells you nighttime dosing worked. It does not tell you daytime dosing would not have, because that arm was never tested.
The sleep connection, from a different angle
A separate line of evidence, not a sermorelin trial at all, adds real weight to the mechanism, though it has to be read carefully for what it actually studied. A randomized, sham-controlled trial gave men with obstructive sleep apnea either real or sham CPAP therapy for 12 weeks. CPAP, which improves sleep continuity and quality, produced a measurable rise in “total… and pulsatile… GH secretion, mean GH concentration…, mass of GH secreted per pulse…, and pulse frequency” compared to sham treatment [3]. In plain terms: improving the quality of someone’s sleep increased their own pulsatile GH output, independent of any drug.
That is genuinely supportive of the broader nighttime-dosing logic — sleep quality and GH pulsatility are linked, and that link exists whether or not sermorelin is involved. It is not, however, a sermorelin study, and it should not be read as one. It is evidence about sleep and GH physiology in general, borrowed to explain why a GHRH analog’s timing choice has a real mechanistic basis, not evidence that sermorelin itself performs differently at 10pm than at 10am.
Two facts, kept separate on purpose
It is tempting to connect these, and the connection has not been tested. The physiology review’s note about sex differences in pulsatile GH secretion, and the sermorelin trial’s men-only lean-mass finding, are two separate, real observations from two separate sources [1][2]. Whether one explains the other has never been studied. Treat them as parallel facts, not a proven relationship. Connecting them convincingly would take a trial nobody has run.
What has not been tested
No published trial has compared sermorelin dosed at night against sermorelin dosed at a different time of day, in the same people, measuring the same outcomes. The entire evidentiary basis for nighttime dosing is: general GH physiology says nighttime release predominates, and the one positive adult trial happened to use nighttime dosing and got a real result [1]. That is a coherent, physiologically grounded argument. It is not a head-to-head comparison, and it should not be described as one. For what that trial did and did not show about outcomes, the full results are covered here.
What about people who do not sleep at night
This is a genuinely open question, worth naming rather than skipping past. Shift workers, people with irregular sleep schedules, and anyone whose “night” does not line up with everyone else’s clock are a real, sizable group — and the mechanism this whole article rests on is tied to sleep, not literally to the hour on a clock. If pulsatile GH release tracks sleep architecture rather than darkness itself, the more physiologically coherent target might be your own main sleep period, whatever hours that falls on. That is a reasonable extension of the mechanism. It has not been tested in shift workers, or in anyone with an inverted schedule, using sermorelin or any GHRH analog. “Dose at night” should not be read as a rule that simply breaks down for a night-shift nurse, but nobody has measured what the right substitute rule actually is, either. That gap sits squarely in “no trial has measured this” territory, and it deserves to be named as exactly that.
The bottom line
Nighttime dosing is not an arbitrary convention borrowed from other injectables. It lines up with when your pituitary already prefers to release growth hormone. The one trial that used it produced a fast, measurable nocturnal GH rise [1]. What it is not is proven superior to any alternative timing, because no trial has run that comparison. The honest sentence is “night makes mechanistic sense, and it is what worked in the one trial we have,” not “night has been proven better than day.” Sellers that state their dosing schedule plainly, rather than dressing it up as settled science, are worth weighing against the injections board.